ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025
Myeloid-derived suppressor cells modulation in the context of tumor microenvironment for gastric cancer.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global research trends in signaling pathways of spasmolytic polypeptide-expressing metaplasia pathogenesis: a bibliometric analysis.Frontiers in oncology · 2025Pooled it
- Advances inOncology letters · 2026Review
- Spatial omics and its applications for a tumour microenvironment characterization and precision medicine approach of gastric cancer.Ecancermedicalscience · 2026Review
- Metabolic reprogramming networks in the gastric cancer tumor microenvironment: an integrated axis of nutrient competition, metabolic crosstalk, and immunosuppression.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) exhibits aggressive behavior and high mortality rates globally. In this respect, the effectiveness of chemotherapy and immunotherapy is hindered by various factors including tumor heterogeneity, immune phenotypes, chronic H. pylori infection, and an immunosuppressive tumor microenvironment (TME). The immunosuppressive TME is fostered by multiple immune cell subpopulations as tumor-associated neutrophils, tumor-associated macrophages, tumor-associated dendritic cells, regulatory T cells, and myeloid-derived suppressor cells (MDSCs). The MDSC abundantly infiltrates gastric TME, which interacts with H. pylori infection and is influenced by reactive oxygen species (ROS), chronic inflammation, and hypoxia. Understanding its cellular and molecular biology of GC is crucial for developing novel therapeutic options. Current preclinical evidence is emerging to support translational oncology on MDSC immunotherapy. This article review suggests MDSC modulation may be a promising avenue for enhancing chemotherapy and immunotherapy responses against GC.
Indexed as
Identifiers
40555972What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.